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Abstract 
Background 
The effect of the increased awareness of the potential to treat cancer during pregnancy is currently unknown. The 
International Network on Cancer, Infertility and Pregnancy (INCIP) registers the incidence and maternal, 
obstetrical, oncological and neonatal outcome of cancer occurring during pregnancy. In this INCIP study, we 
aimed to describe the oncological management and the obstetrical and neonatal outcomes of patients treated in 
the last 20 years and evaluate their changes over time. Further, we evaluated associations of malignancy type and 
treatment with obstetrical and neonatal outcomes. 
Methods 
This descriptive cohort study involved data from pregnant patients with cancer registered by all 37 centres (from 
16 countries) participating in the INCIP registry. Oncological, obstetrical and neonatal outcome data of 
consecutive patients diagnosed with primary invasive cancer during pregnancy between 1996 and 2016 were 
retrospectively and prospectively collected. We analysed changes over time with log-binomial regression. We 
used multiple logistic regression to analyse preterm pre-labour rupture of membranes (PPROM) and/or 
contractions, small for gestational age (SGA), and neonatal intensive care unit (NICU) admission. In these 
models, malignancy type, six chemotherapeutic agents (alkylating, anthracyclines, antimetabolite, taxanes, 
platinum, and any other agent), and abdominal and/or cervical surgery were the key covariates, prespecified 
confounding variables were time period of diagnosis, age at diagnosis, diagnosis in 3
rd
 pregnancy trimester, and 
systemic disease. The INCIP registry is registered with ClinicalTrials.gov (NCT00330447), and is ongoing.  
Findings 
1170 patients were included. Breast cancer was the most common malignancy (n=462, 39%). 779 patients (67%) 
received treatment during pregnancy. Every five calendar years, treatment during pregnancy increased by 10% 
(95% CI 5 to 15). This increase was mainly related to an increase of chemotherapeutic treatment by 31% every 
five calendar years (95% CI 20 to 43). Overall, 995/1089 singleton pregnancies ended in a live birth (88%) of 
which 429 (48%) ended preterm. Every five calendar years, 4% more live births (95% CI 1 to 6), and 9% less 
iatrogenic preterm deliveries (95% CI 2 to 16) were reported. Our data suggested a relationship between 
platinum-based chemotherapy and SGA (odds ratio 3·12, 95% CI 1·45 to 6·70), and between taxanes and NICU 
admission (odds ratio 2·37, 95% CI 1·31 to 4·28). NICU admission was suggested to depend on malignancy 
  
type, with gastro-intestinal cancers having highest risk (odds ratio vs. breast cancer 7·13, 95% CI 2·86 to 17·7) 
and thyroid cancers having lowest risk (odds ratio vs. breast cancer 0·14, 95% CI 0·02 to 0·90). Unexpectedly, 
the data suggested that abdominal and/or cervical surgery was related to a lower NICU admission rate (odds ratio 
0·30, 95% CI 0·17 to 0·55). Other associations of treatment and malignancy type were less clear.  
Interpretation  
Over the years, we observed that more patients with cancer during pregnancy received antenatal treatment, 
especially chemotherapy. Our data indicate that patients with antenatal chemotherapy exposure may have an 
increased risk to develop pregnancy related complications, specifically SGA and NICU admission. We therefore 
recommended involving hospitals with obstetrical high care units in the management of these patients. 
Funding 
Research Foundation-Flanders, European Research Council, Charles University, Ministry of Health of the Czech 
Republic.  
  
Introduction 
Based on several national-wide studies, the incidence of cancer during pregnancy is estimated to be one in 1000 
pregnancies.
1-3
 Breast cancer, haematological cancer, cervical cancer and melanoma are the most commonly 
diagnosed malignancies during pregnancy.
4,5
 Awareness of this subject has increased the number of cohort 
studies on maternal and foetal outcome in these women.
4,5
 These studies focused on overall maternal and 
obstetrical outcome, but their population size or follow-up is limited. 
In 2010, our group published the first epidemiologic data on cancer during pregnancy based on the registry of the 
International Network on Cancer, Infertility and Pregnancy (INCIP).
4
 Few years later, Amant et al.
6,7
 published 
two prospective follow-up studies of children with antenatal chemotherapy exposure. They found no clinical 
difference in neurocognitive and cardiac development between the treatment and the control group. In both 
groups, preterm delivery was the main risk factor for paediatric developmental problems up to three years of 
age.
7
 These studies showed reassuring results on the neonatal and infant outcome up to three years and 
strengthened the overall idea that oncological treatment in pregnancy is feasible. However, the effect of antenatal 
chemotherapy on secondary malignancies or fertility later in life is still not known. Antenatal exposure to cancer 
treatment, and especially chemotherapy, was associated with a higher proportion of small-for-gestational-age 
(SGA) children in some studies,
4,6,8,9
 while others did not find such an association.
2,10
 Also, several studies 
described an increased preterm delivery rate in patients with cancer during pregnancy.
2,4,8
 Nevertheless, these 
studies were often small and could not identify which patients with cancer in pregnancy are at risk for negative 
obstetrical or neonatal outcome.  
The aim of this study is to describe the oncological, obstetrical and neonatal data of the INCIP registry and to 
evaluate changes in obstetrical management and neonatal outcome over the last 20 years. We hypothesized that 
over the years more patients were treated during pregnancy, which might have influenced the obstetrical and/or 
neonatal outcome. Further, we investigated whether type of malignancy or treatment modalities might be related 
to adverse obstetrical or neonatal outcomes within the group of patients with cancer during pregnancy. We 
hypothesized that chemotherapy during pregnancy might have resulted in a higher number of adverse outcomes. 
We were particularly interested in the following outcome measures because they were relatively common: 
preterm prelabour rupture of membranes (PPROM) and/or preterm contractions, SGA and neonatal intensive 
care unit (NICU) admission. See Appendix, page 3.  
 
  
Methods 
Study design and patients 
This was a descriptive cohort study that involves data from pregnant patients with cancer registered by all 37 
centres (16 countries) participating in the INCIP registry. The INCIP was established in 2005 to evaluate 
oncological care and obstetrical, maternal and neonatal outcome in women with cancer during pregnancy 
(www.cancerinpregnancy.org). The aim was to register consecutive patients both retrospectively and 
prospectively. Before 2005, all patients were included retrospectively, after 2005 it depended on the date on 
which a centre started participating to our study. To include retrospective patients in a most consecutive order, 
hospitals used patient databases to identify all eligible patients within their hospital. Patient data were registered 
upon written informed consent of the patients. This study was approved by the Ethical Committee of University 
Hospital Leuven (Belgian number B322201421061).  
Patients diagnosed between 01/01/1996 and 10/18/2016 with primary invasive cancer and borderline ovarian 
cancer during pregnancy, were eligible. Patients with pre-invasive disease or postpartum diagnosis were 
excluded. Detailed oncologic, obstetric and neonatal data were collected. Diagnosis was made using local 
standards, but all included histopathological confirmation. We divided our cohort in 3 subgroups according to 
year of diagnosis: 1996-2004 (group 1); 2005-2009 (group 2); 2010 - November 2016 (group 3). The 
differentiation between group 1 and 2 was based on the start of our online registration study in 2005, after which 
most registrations were prospective. The differentiation between group 2 and 3 was based on the publication date 
of the first INCIP report.  
Systemic disease was defined as TNM or FIGO stage IV disease and leukaemia, non-systemic disease was 
defined as TNM or FIGO stage I to III and all brain cancers. For the variable ‘surgery during pregnancy’, we 
only included therapeutic surgical procedures. PPROM was assessed following local protocol and was defined as 
preterm rupture of membranes without contractions. Perinatal mortality was defined according to the WHO 
guidelines as the number of stillbirths and deaths in the first week after birth. Major and minor congenital 
malformations were defined according to Eurocat (www.eurocat-network.eu). Birthweight percentiles were 
calculated according to the percentile calculator from www.gestation.net (v6·7·5·7(NL), 2014). The included 
parameters are shown in the Appendix, page 4. Birthweight below the 10
th
 percentile was considered as SGA. 
This study is registered as an International Observational Cohort study with ClinicalTrials.gov (NCT00330447) 
and approval was obtained from all participating centres and authorities. See 
  
http://www.cancerinpregnancy.org/study-protocols for the full study protocol, this manuscript is based on study 
part I and the primary objective of this study lies within the wider primary objective of the study protocol.   
Statistical analysis 
No dedicated sample size calculation was performed for this descriptive study. We agreed upon an analysis 
strategy beforehand, did not adapt this strategy based on obtained results, and fully reported all results. We 
provide descriptive statistics of oncological, obstetrical, and neonatal information. Then, we analysed the 
relationship of malignancy type and treatment modalities with obstetrical and neonatal outcomes (PPROM 
and/or preterm contractions, SGA, and NICU admission) with multiple logistic regression models using Firth 
bias correction. We stress that these models do not include a control group of patients without cancer, but 
compare patients with cancer during pregnancy with respect to the presence or absence of different 
characteristics or exposures. For the obstetrical outcome PPROM and/or preterm contractions, we based the 
regression analysis on the sample of singleton live births and stillbirths. For the two neonatal outcomes, we 
based the analysis on the sample of singleton live births only. Both outcome variables and covariates in the 
models were fully pre-specified. Key covariates in the models were malignancy type, six chemotherapeutic 
agents (alkylating, anthracyclines, antimetabolite, taxanes, platinum, and any other agent), and abdominal and/or 
cervical surgery. We added the following potential confounding variables without further data-driven variable 
selection: time period of diagnosis, age at diagnosis, diagnosis in 3
rd
 pregnancy trimester, and systemic disease. 
We did not consider interaction terms. Alkylating chemotherapeutic agents were divided into platinum and other 
alkylating agents due to the relatively higher placenta passage of carboplatin compared to other agents in baboon 
models and the high placental passage of cisplatin in humans.
11,12
 We reported adjusted odds ratios (OR) with 
95% confidence intervals (CI) from the multiple logistic regression models. We report p-values to measure the 
strength of the evidence against the null hypothesis of no relationship, but do not specify an alpha level and 
hence do not determine statistical significance. For the multiple regression models, we handled missing values 
for covariates or outcomes using multiple imputation (See Appendix, page 5).
13
 As a sensitivity analysis, we 
compared results based on imputed data with results based on complete case analysis.  
For the descriptive analysis and evaluation of changes over 20 years in categorical patient characteristics, 
outcomes, and treatment modalities, we use univariable log-binomial regression models with year of diagnosis as 
a continuous predictor. We express results using relative risks (RR) to describe the average change every five 
calendar years (See Appendix, page 6), together with 95% confidence intervals. For continuous parameters, we 
  
use univariable linear regression with year of diagnosis as continuous predictor, with results expressed as 
average change every five calendar years. Statistical significance was not determined. For this analysis, we did 
not impute missing data but rather used available cases. This analysis was prespecified, and was performed and 
reported for all parameters of interest. 
The analysis was performed using R 3·3·1 (www.r-project.org).  
Role of the funding source 
The financial funders had no role in the study design, data collection, data analysis, interpretation of the data or 
in writing of the report. The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.  
 
Results 
The trial design is depicted in Figure 1. In total, 1170 consecutive patients were eligible from 37 centres in 16 
countries. The distribution of countries with highest accrual was as follows: Belgium (319, 27%), the 
Netherlands (278, 24%), Italy (179, 15%), Russia (135, 12%) and Czech Republic (100, 9%). Specifications of 
inclusion are in Appendix, page 7 and 8. An overview of missing values is given in Appendix, page 9 and 10). 
Oncological information 
Baseline characteristics are shown in Table 1, distribution of malignancies and stage of disease per malignancy 
are depicted in Figure 2A and 2B, respectively. Seventy-nine percent (893/1125) of patients had non-systemic 
disease. Forty-five percent (n=490/1098) of patients were diagnosed in the second trimester, whereas 24% in 
first and 24% in third trimester (Appendix, page 11 for specification per malignancy).  
Of all 1170 patients, 779 (67%) received treatment during pregnancy, of which 574 received a single treatment 
modality (74%) and 205 a combination of different treatment modalities (26%) (Table 2; Appendix, page 12). 
Surgery was the most common therapy in patients with thyroid cancer, ovarian cancer or melanoma. 
Chemotherapy was the most common treatment modality in patients with lymphoma or breast cancer. The 
majority of patients with cervical or brain cancer were not treated during pregnancy (respectively 56% and 52%). 
Specification of the different chemotherapeutic agents given during pregnancy can be found in Table 1. 
Combination regimens consisting of more than one chemotherapeutic agent were registered in 351/423 (83%) 
  
patients. Abdominal and/or cervical surgery was performed in 149 patients. Sixty-nine percent (98/143) of these 
patients had stage I disease and for 70% (104/149) surgery was the only treatment modality performed during 
pregnancy.  
Obstetrical information 
Of all 1142 pregnancies with known obstetrical outcome, 25 (2%) ended in a miscarriage and 113 (10%) were 
terminated. Sixty-two percent (64/103) of terminations were performed in the first trimester, 38% (n=39/103) in 
the second trimester. For 10 patients, GA at termination was unknown. Main reasons for termination were start 
of oncological treatment or poor maternal prognosis (77%), unwanted pregnancy (10%), and foetal anomalies 
(4%). Information on differences in number of terminations per period of diagnosis and malignancy type can be 
found in Appendix, page 13. Of the ongoing pregnancies, there were 27 twin pregnancies and 1 triplet 
pregnancy. Five (<1%) patients died during pregnancy. For the obstetrical outcomes, only data from singleton 
live births and stillbirths are reported and is summarized in Table 3.  
Of the 969 ongoing singleton pregnancies, seven (1%) intra-uterine fetal deaths and seven (1%) perinatal deaths 
were reported, see Appendix, page 14 for detailed information on these cases. All other 955 pregnancies (99%) 
ended in a live birth. Preterm delivery rate was 48% (429/887, excluding 68 cases with missing GA at birth). 
Eighty-eight percent (373/425) of preterm deliveries was iatrogenic. PPROM and/or preterm contractions 
(98/969, 10%) was the most reported obstetrical complication (Appendix, page 15). From all these patients, 52 
patients actually delivered spontaneously before 37 weeks (53%).  
Neonatal outcome 
For neonatal outcomes, only data from singleton live births are reported. Percentages of missing data in singleton 
live births are presented in Appendix, page 16. Birth weight percentiles were calculated in 796/955 (83%) 
singleton live births for which birth weight and GA at delivery were known (Appendix, page 16). Data on all 
neonatal outcomes stratified by different variables are shown in Appendix, page 17. 167/796 children (21%) 
were SGA. Information on neonatal intensive care unit (NICU) admission was available for 720/955 (75%) 
children, with an admission rate of 41% (298/720). NICU admission was mainly prematurity related (249/298, 
84%). The presence of congenital malformations was reported in 32/721 (4%) live born singletons, with 17 (2%) 
minor and 15 (2%) major malformations (2·5-3% major malformations are reported in general population
14
). 
Three other pregnancies were terminated because of foetal anomalies (hydrocephalus, trisomy 21 and 
  
unspecified major malformations). Anomalies did not differ between the different treatment modalities. 
(Appendix, page 19) 
Association of malignancy type and treatment modalities with adverse obstetrical or neonatal outcomes 
Here we describe results for the key variables (malignancy type, administration of chemotherapeutic agents, and 
abdominal and/or cervical surgery). Full results of the multiple logistic regression models, including associations 
for the prespecified potential confounders (age at diagnosis, period of diagnosis, trimester at diagnosis, and 
systemic disease), can be found in Table 4. Model coefficients and standards errors can be found in the 
Appendix, page 20. 
The multiple regression model for SGA provided support for a relationship between chemotherapy and SGA, in 
particular for platinum-based chemotherapy (OR 3·12, 95% CI 1·45-6·70). Other agents like non-platinum 
alkylating chemotherapy or taxanes may also be related (OR>2), but results were more uncertain. Malignancy 
type and abdominal and/or cervical surgery had a weak relation with SGA (Table 4; Appendix page 21). 
For NICU admission, there appears to be a strong independent association with malignancy type: gastro-
intestinal cancers had the highest admission rates (OR 7·13 vs. breast cancer, 95% CI 2·86-17·7), thyroid cancer 
to the lowest (OR 0·14 vs. breast cancer, 95% CI 0·02-0·90) (Appendix page 22). There was again support for 
an association between chemotherapy and NICU admission, in particular for taxanes (OR 2·37, 95% CI 1·31-
4·28). Finally, the data suggested that abdominal and/or cervical surgery was related to a lower NICU admission 
rate (OR 0·30, 95% CI 0·17-0·55). 
For PPROM, the least common of the three investigated complications with 98 registered instances, results were 
largely inconclusive for all variables (Table 4; Appendix page 23). This was the least common of the 
investigated outcomes, resulting in high standard errors (Appendix, page 20). The relationship between 
chemotherapy and PPROM is in line with our hypothesis, with OR>2 for the platinum and non-platinum based 
alkylating agents. 
The sensitivity analysis based on complete cases provided highly similar results (Appendix, page 24). 
Changes over 20 years 
Specification of descriptive statistics per time period, and analysis of change over time is given in Appendix 
page 25.  An overview of the most important changes per period can be found in Figure 3. Every five calendar 
  
years, there was an increase of 10% in the number patients who received treatment during pregnancy (RR 1·10, 
95% CI 1·05 to 1·15). Also, every five years, 31% more patients received chemotherapy during pregnancy (RR 
1·31, 95% CI 1·20 to 1·43), and only 1% less patients underwent surgery (RR 0·99, 95% CI 0·92 to 1·07). 
Radiotherapy became less frequent and targeted therapy more frequent, but these modalities were uncommon in 
general. Every five years, we observed an increase of 2·6 days (95% CI -1·1 to 6·3) in the GA of the last 
chemotherapy cycle given during pregnancy.  
Every five years, there were 4% more live births among singletons (RR 1·04, 95% CI 1·01 to 1·06), 7% fewer 
preterm live births (RR 0·93, 95% CI 0·86 to 0·99), and 9% fewer iatrogenic preterm live births (RR 0·91, 95% 
CI 0·84 to 0·98). In line with the declining number of preterm deliveries, every five years, NICU admissions 
decreased with 9% every five years (RR 0·91, 95% CI 0·83 to 0·99). The occurrence of SGA increased 16% 
every five years (RR 1·16, 95% CI 0·99 to 1·35). We observed a 3% decrease in PPROM and/or preterm 
contractions every five years (RR 0·97, 95% CI 0·80 to 1·18). 
 
Discussion 
Our data suggested a relationship between platinum-based chemotherapy and SGA, and between taxanes and 
NICU admission. NICU admission was suggested to depend on malignancy type. Unexpectedly, the data 
suggested that abdominal and/or cervical surgery was related to a lower NICU admission rate. Other associations 
of treatment and malignancy type were less clear. Over 20 years, we observed an increased number of 
pregnancies ending in a live birth that coincide with cancer together with an increase of 31% every five years in 
patients treated with chemotherapy during pregnancy (Appendix, page 25). In line with the increasing 
chemotherapy rates over the years, SGA also increased with 16% every five calendar years. These results 
strengthen the recommendation to involve hospitals with obstetrical high care units in the management of 
pregnant cancer patients with these risk factors. The complexity of dealing with two patients at once stresses the 
need for a multidisciplinary approach.  
The reason for the observed increased rate of chemotherapy during pregnancy in combination with an increase of 
live births may be attributed to changing treatment regimens during the period of registration in combination 
with reassuring results on antenatal chemotherapy exposure. Since 1996, 25 cohort studies including more than 
50 patients were published on the subject of cancer during pregnancy with a focus on obstetrical outcome 
  
(Appendix, page 26). In summary, a high rate of preterm birth was observed, but the relation between SGA and 
cancer treatment during pregnancy remained inconclusive. Several studies describe a reassuring foetal outcome 
after chemotherapy during pregnancy. No congenital, neurologic or psychologic abnormalities were detected in 
children antenatal exposed to chemotherapy.
7,15,16
 These reassuring fetal, neonatal and infant outcome up to three 
years, together with the similar maternal survival rates compared to non-pregnant women diagnosed and treated 
for cancer, are potential factors for the increase of cancer treatment over time as observed in our analysis.  
The current study confirms the high overall prematurity rate (48%) in patients with cancer during pregnancy, as 
published by several previous cohort studies (Appendix, page 26). Preterm birth is related to an increased risk of 
perinatal morbidity and mortality, and neurodevelopmental impairment later in life. There is a direct correlation 
between a lower GA at delivery and negative outcome.
17
 Lu et al.
8
 observed an increased risk of neonatal 
mortality in patients with cancer during pregnancy (IRR 2·7, 95% CI 1·3 to 5·6), which was caused by 
prematurity in 89% of the cases. Our study found inconclusive results on the association between antenatal 
chemotherapy exposure and PPROM and/or contractions. As for other risk factors for spontaneous premature 
delivery, we hypothesised that patients undergoing abdominal and/or cervical surgery would be at greater risk of 
PPROM and/or preterm contractions. Our multiple regression analysis did not support such an effect. It may be 
explained by the high number of stage I disease (69%) and surgical therapy only (70%) in this group of patients, 
as these patients have no potential risk factors for adverse obstetrical or neonatal outcome.
18,19
  We observed a 
decline of the preterm birth rate during the registration period of 7% every five calendar years, which was mainly 
attributed to the lower iatrogenic prematurity rate. This decline may be attributed to the tendency to continue 
chemotherapy longer during pregnancy to postpone delivery for the benefit of the child. Although, we realize 
that the effect of 2·6 days (95% CI -1·1 to 6·3) every five years is not strong. This may be explained by the fact 
that reassuring results on antenatal chemotherapy were published only a few years ago and that the follow-up in 
this cohort is not long enough to fully evaluate this change.  
The tendency to treat more patients with chemotherapy during pregnancy may also have adverse consequences. 
We reported an increased incidence of SGA. Preterm birth, perinatal morbidity and mortality in the first weeks 
and cardiovascular and metabolic diseases later in life are more frequently seen in these children.
20,21
 Several 
studies have highlighted an increased rate of SGA in children from patients with cancer during pregnancy 
(Appendix, page 26). Still, influences of supportive medication, stress and malnutrition cannot be excluded.   
We hypothesized a relationship between systemic disease and SGA, for which our analysis provided mild 
support. In these patients, nutritional state besides other factors, such as general condition, fatigue and circulating 
  
cytokines, may be compromised compared to patients with localized malignancy, irrespective of the treatment 
given.  
Our study further suggests a relationship between chemotherapy, mainly platinum-based agents, and SGA, as 
hypothesized. Several reasons may contribute to such a relationship. Chemotherapeutic agents have several toxic 
properties of which some cause direct damage to the DNA or interfere with DNA replications (e.g. alkylating 
agents, antimetabolites). These direct DNA damage might influence the placental development and its blood 
supply towards the fetus. Additional indirect effects of chemotherapy (induction of vasculopathy or 
inflammation), or the maternal illness itself (associated with malnutrition, anaemia, and high maternal stress) 
may further contribute to restricted foetal growth.
22-24
 Besides the impact of chemotherapy on foetal growth, the 
maternal age has an additional impact, but also influences of supportive medication, stress and malnutrition can e 
contributively.  
Fortunately, the lower birth weights in chemotherapy-exposed children recover, with normal values for weight, 
height, and head circumference in the first months of childhood.
6,7
  
In pregnant patients with cancer, it is important to recognize obstetrical and neonatal risks associated with cancer 
and its treatment modalities. The tendency to avoid preterm deliveries by cancer treatment during pregnancy 
needs to be balanced against an increased risk of SGA children. The short- and long-term risks of SGA are 
important to consider, nevertheless the risk of preterm birth is also of great importance. More long-term research 
comparing the risks in these two groups is necessary.  
To our knowledge, this cohort is the largest cohort on cancer in pregnancy. This study adds to the identification 
of patients at high risk for obstetrical and neonatal complications. However, limitations to this study need to be 
addressed. First, we observed missing data for the neonatal outcomes. This can be attributed to the participating 
hospitals, of which some are either specialized in oncology or obstetrics and perinatology, leading to lack of 
either oncological or obstetrical and neonatal information. Due to the necessity to report obstetrical 
complications when observed, but no explicit mention of the absence of complications, it is possible that the 
occurrence of obstetrical complications is underreported. Second, since we only documented sampling data from 
our online database registered on a voluntary basis by the participating centres of INCIP including 
retrospectively included cases, the incidences of the different tumour types and percentages of the treatment 
modalities given during pregnancy may also differ from these in the worldwide pregnant population. Although 
all participating centres however acknowledged to have registered all their consecutive cases rigorously, some 
selection bias for retrospectively included cases cannot be excluded. Third, a common issue in observational 
  
studies is the presence of confounding, in our case between treatment and patient or tumour characteristics. 
Fourth, due to the rarity of cancer in pregnancy and the changes in cancer treatment over the last years, we 
encountered small group sizes for some malignancies and treatment modalities of which subgroup analysis was 
not possible.  
The observation of increased SGA with chemotherapy exposure needs further research. In our study percentiles 
were calculated at birth, not knowing if there is a specific decrease seen from start of chemotherapy. However, 
the measurement of foetal weight percentiles accurately during pregnancy is difficult, since it is dependent on the 
observer, and there are no foetal charts available worldwide which include ethnic and gender differences and the 
impact of the parental weight and height.  
Further research on placental pathophysiology and the effect of specific chemotherapeutic agents, as well as 
increasing the number of patients in the small subgroups of rare tumour types and treatment modalities, are 
needed to provide all patients confronted with cancer during pregnancy the best tailor made management plan 
optimize both obstetrical and neonatal outcome. Participation to the online registry (incipregistration.be) is 
recommended in order to accomplish this goal. 
 
Research in context 
Evidence before this study 
We searched PubMed on 03/30/2017 for articles on cohorts of patients with cancer during pregnancy describing 
obstetrical and oncological outcome published between 01/01/1996 and 12/31/2016, using the following 
keywords: pregnancy, cancer, tumour, neoplasm, pregnancy outcome and neonatal outcome. The search was 
restricted to publications in English. A review of references from appropriate articles was done to identify 
additional studies. This resulted in a large number of articles on cancer before or after pregnancy but not 
specifically during pregnancy. After selection by abstract and full-text, a total of 71 studies including from n=9 
to n=984 patients. A cohort was considered large and was included if it contained 50 or more patients. This has 
led to a total of 25 articles describing either obstetrical and/or neonatal outcome. No articles on management 
changes were published. Nine cohorts described the complete group including all sort of malignancies, 5 
described breast cancer during pregnancy, 4 haematological cancers, 3 melanoma and 1 cervical cancer, 1 
ovarian cancer, 1 thyroid cancer. Overall, 23 studies reported risk or rates of prematurity; 12 found an increased 
  
rate or risk of prematurity in cancer in pregnancy and 4 studies did not find an increase. Neonatal outcome was 
reported to some extent in all studies. One study found an increased rate or risk of neonatal mortality, while 10 
did not find such an increase. Increased risk of NICU admission was found in 1 study, while 3 found no such 
increase. Overall SGA was specified in 22 articles and was increased in 5 articles, while 13 studies did not find 
an overall increased risk of SGA. None of the studies found an increased rate or risk of congenital anomalies. 
Added value of this study 
To our knowledge, this is the largest cohort describing both detailed information on clinical management and 
obstetrical and neonatal outcome. The multiple regression analysis suggested that antenatal chemotherapy may 
increase the risk of neonatal complications. For SGA, mainly platinum-based chemotherapeutic agents appeared 
influential. Also, this is the first study evaluating the changes in clinical management and obstetrical and 
neonatal outcome over years. It appears that during the last 20 years more mothers to be were treated with 
chemotherapy during pregnancy, resulting in more live births and less prematurity. This observation is indicative 
of an increased knowledge and awareness about cancer treatment during pregnancy. 
Implications of all available evidence 
Our study suggests that over the years, oncological treatment during pregnancy increased and prematurity rates 
decreased. Less prematurity adds to a better neonatal and long-term paediatric outcome. However, the use of 
chemotherapy during pregnancy may cause neonatal complications like SGA and NICU admission. The long-
term paediatric outcome needs to be assessed in more long-term follow-up studies of these children. With the 
suggested risk factors from our study, it is possible to assess pregnant cancer patients better and refer these 
obstetrical high risk patient to an academic hospital, where close surveillance in a multidisciplinary setting is 
provided. Here, paramedical support, psychological guidance and breastfeeding information additionally 
contribute to an optimal approach.  
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Table 1. Patient characteristics.  
Characteristic Result 
All patients, n=1170 
Age at diagnosis in years  
Median (IQR) 32 (29-36) 
Range 16-53 
Missing, n 13 
Period of diagnosis  
1996 – 2004 257 (22) 
2005 – 2009 376 (32) 
2010 – 2016 537 (46) 
Trimester of diagnosis, n (%)a  
Pregnant during treatment 76 (7) 
First trimester 266 (24) 
Second trimester 490 (45) 
Third trimester 266 (24) 
Missing 72  
Parity at diagnosis, n (%)  
Nulliparous 486 (44) 
Multiparous 625 (56) 
Missing 59 
Stage of disease  
Local or regional 893 (79) 
Systemicb 232 (21) 
Missing 45 
Treatment received during pregnancy, n (%)c  
No treatment during pregnancy 391 (33) 
Surgery 454 (39) 
- Abdominal/cervical surgery 149 (33) 
Chemotherapyd 429 (37) 
- Anthracyclines 328 (78) 
- Alkylating (excl. platinum)  292 (69) 
- Antimetabolite 108 (26) 
- Taxanes 84 (20) 
- Platinum 74 (18) 
- Other 97 (23) 
- Missing 6 
Radiotherapy  29 (3) 
Targeted therapy 33 (3) 
Other therapy 52 (4) 
All singleton live & still births, n=969 
Adverse obstetrical outcome  
PPROM and/or preterm contractions 98 (10) 
All singleton live births, n=955 
Adverse neonatal outcome  
Small-for-gestational-age  167/796 (21) 
Neonatal intensive care unit admission 298/720 (41) 
PPROM, preterm prelabour rupture of membranes 
a 
Stratification per malignancy group can be found in the Appendix, page 11. 
b 
Systemic disease was defined as TNM or FIGO stage IV disease and leukaemia, non-systemic disease was 
defined as TNM or FIGO stage I to III and all brain cancers. 
c 
Patients with multiple treatment modalities during pregnancy are placed in all applicable groups, hence 
percentages add up to more than 100. Stratification per malignancy group of the different treatment 
combinations given during pregnancy is shown in Appendix, page 12. 
d 
Combination regimens consisting of more than one chemotherapeutic agent were registered in 83% of the 
patients.  
 
 
  
Table 2. Overview of different treatment modalities per malignancy for all 1170 patients. Patients with multiple treatment modalities during pregnancy are placed 
in all applicable groups. 
 Total No treatment Surgery Chemotherapy Radiotherapy Targeted and 
hormonal 
therapya 
Other therapyb 
 n n (%) n (%) n (%) n (%) n (%) n (%) 
Breast 462 116 (25) 225 (49) 248 (54) 12 (3) 7 (2) - 
Cervix 147 83 (56) 32 (22) 37 (25) 2 (1) - - 
Lymphoma 113 41 (36) 8 (7) 66 (58) 4 (4) 18 (16) - 
Ovarian 88 23 (26) 64 (73) 21 (24) - - - 
Leukaemia 68 22 (32) - 23 (34) 1 (1) 7 (10) 15 (22) 
Gastro-intestinal 49 19 (39) 21 (43) 16 (33) - - - 
Melanoma 46 12 (26) 33 (72) - 2 (4) - - 
Thyroid 37 7 (19) 30 (81) - 1 (3) - - 
Brain 21 11 (52) 10 (48) 1 (5) 1 (5) - - 
Other 139 57 (41) 31 (22) 17 (12) 6 (4) 1 (1) 37 (27) 
Total 1170 391 (33) 454 (39) 429 (37) 29 (2) 33 (3) 52 (4) 
a 
Targeted and hormonal therapy include rituximab n=18, imatinib n=7, trastuzumab n=3, tamoxifen n=3, lorlatinib n=1 and trastuzumab + pertuzumab n=1.  
b 
Other therapies include interferon n=52. 
 
  
Table 3. Obstetrical outcome, stratified by malignancy for all singleton pregnancies with known 
obstetrical outcome, n=1089/1107, 98%). 
 Total Miscarriage TOP Still birtha Live birth < 
37 weeks 
Live birth ≥ 
37 weeks 
Live birth 
GA 
Unknown 
Maternal 
death 
during 
pregnancy 
Malignancy n n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Breast cancer 428 6 (1) 26 (6) 1 (<1) 184 (43) 182 (43) 28 (7) 1 (<1) 
Cervical cancer 140 2 (1) 21 (15) 2 (1) 72 (51) 37 (26) 6 (4) - 
Lymphoma  107 - 8 (8) 3 (3) 48 (45) 45 (42) 3 (3) - 
Ovarian cancer 83 3 (4) 3 (4) - 21 (25) 53 (64) 3 (4) - 
Leukaemia 64 5 (8) 6 (9) 2 (3) 26 (41) 25 (39) - - 
Gastro-intestinal 
cancer 
47 2 (4) 4 (9) 2 (4) 29 (62) 8 (17) 1 (2) 1 (2) 
Melanoma 43 - 2 (5) - 3 (7) 34 (79) 3 (7) 1 (2) 
Thyroid cancer 37 - 4 (11) - 1 (3) 32 (87) - - 
Brain cancer 19 - 2 (11) - 9 (47) 6 (32) - 2 (11) 
Other 
malignancies 
121 2 (2) 19 (16) 4 (3) 37 (31) 36 (30) 23 (19)   - 
Total 1089 20 (2) 95 (9) 14 (1) 430 (40) 458 (42) 67 (6) 5 (1) 
TOP, termination of pregnancy; GA, gestational age;  
a 
Still births consisted of 7 intra-uterine deaths, 7 perinatal deaths.  
  
  
Table 4. Multivariable analysis of the most common obstetrical and neonatal complications. For preterm 
prelabour rupture of membranes (PPROM)/preterm contractions, we analysed singleton stillbirths and 
live births (n=969), for the neonatal complications we analysed singleton live births (n=955). We handled 
missing data using multiple imputation. 
 PPROM/preterm 
contractions 
Small-for-gestational-age Neonatal intensive care unit 
admission 
Covariate OR 
(95% CI) 
P OR 
(95% CI) 
P OR 
(95% CI) 
P 
Malignancy  
0·16 
 
0·86 
 
<0·0001 
Breast cancer Referencea Referencea Referencea 
Cervical cancer 0·74 (0·27-2·04) 0·75 (0·36-1·55) 2·22 (1·19-4·15) 
Lymphoma 1·24 (0·49-3·12) 1·17 (0·52-2·60) 1·04 (0·53-2·04) 
Ovarian cancer 0·60 (0·16-2·30) 0·39 (0·14-1·09) 0·60 (0·26-1·38) 
Leukaemia 2·45 (0·80-7·48) 0·68 (0·23-2·03) 1·27 (0·53-3·03) 
Gastro-intestinal cancer 0·33 (0·06-1·96) 0·80 (0·29-2·22) 7·13 (2·86-17·7) 
Melanoma 0·76 (0·19-3·12) 0·90 (0·29-2·76) 0·36 (0·13-1·04) 
Thyroid cancer 0·52 (0·09-3·12) 0·73 (0·21-2·58) 0·14 (0·02-0·90) 
Other malignancies 0·44 (0·15-1·31)  0·82 (0·36-1·83) 1·42 (0·73-2·75) 
Period of diagnosis  
0·69 
 
0·32 
 
0·019 
1996-2004 Referenceb Referenceb Referenceb 
2005-2009 0·81 (0·44-1·48) 0·77 (0·45-1·31) 0·73 (0·48-1·11) 
2010-2016 0·77 (0·43-1·39) 1·04 (0·63-1·73) 0·55 (0·36-0·84) 
Age at diagnosis (per 5 years) 1·08 (0·86-1·35) 0·53 1·36 (1·11-1·68) 0·0033 0·98 (0·82-1·17) 0·65 
Diagnosis in 3rd trimester vs. 
before 
0·64 (0·35-1·15) 
0·14 
0·78 (0·48-1·27) 
0·33 
1·13 (0·77-1·65) 
0·52 
Systemic vs. non-systemic 
disease 
1·43 (0·70-2·92) 
0·34 
1·86 (1·04-3·33) 
0·039 
1·14 (0·68-1·93) 
0·52 
Chemotherapeutic agents  
0·056  
 
<0·0001 
 
0·0086c 
Alkylating (yes vs. no) 2·02 (0·81-5·02) 2·08 (0·88-4·91) 0·88 (0·46-1·70) 
Anthracyclines (yes vs. no) 1·11 (0·42-2·92) 0·50 (0·21-1·22) 1·21 (0·62-2·38) 
Antimetabolite (yes vs. no) 0·89 (0·46-1·71) 1·24 (0·70-2·22) 1·03 (0·60-1·74) 
Taxanes (yes vs. no) 1·11 (0·53-2·33) 2·07 (1·11-3·86) 2·37 (1·31-4·28) 
Platinum (yes vs. no) 2·29 (0·79-6·63) 3·12 (1·45-6·70) 1·66 (0·77-3·55) 
Other (yes vs. no) 1·48 (0·61-3·63) 2·34 (1·04-5·25) 1·63 (0·78-3·38) 
Abdominal/cervical surgery 
(yes vs. no) 
0·42 (0·15-1·16) 
0·083 
1·31 (0·67-2·59) 
0·45 
0·30 (0·17-0·55) 
<0·0001 
a We used the largest group as reference category (breast cancer). 
b We used the first time period as reference category (1996-2004) . 
P-values are related to the null hypothesis that all odds ratios to which they refer are 1. For malignancy, these are the odds ratios of all 
malignancy types vs. breast cancer. For period of diagnosis, these are the odds ratios of each period vs. the first. For chemotherapeutic 
agents, the p-value refers to the simultaneous association of the administration all six agents with the outcome. All other p-values refer to 
only one odds ratio. 
 
  
  
Figure 1. Flow chart with inclusion process.   
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having cancer during pregnancy 
n=1295 
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n=12 
 Patients with invasive cancer during 
pregnancy 
n=1283 
 
Patients with primary cancer during 
pregnancy 
n=1195 
 
 
Recurrent cancer during pregnancy 
n=88 
 
Missing essential data for analysis: 
- No date of diagnosis n=8 
- No obstetrical information n=6 
- No treatment specifications n=11  
Total eligible patients 
n=1170 
 
  
Figure 2. Distribution of malignancies during pregnancy (A) and stage of disease (B) at diagnosis per 
malignancy. Stage of disease was available for all solid malignancies with TNM or FIGO classification.  
 
 
 
* Ovarian cancers include borderline ovarian tumours. 
**The group with other malignancies consists of 25 different malignancy types.  
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Figure 3. Changes in management (A) and obstetrical outcome (B) over 20 years. Management changes 
are shown for all 1170 patients, obstetrical outcome is shown for all singleton pregnancies. 
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1. General information.  
 
1.1. Hypotheses prior to start study.  
 
We hypothesized that cancer and cancer treatment during pregnancy results in a higher number of obstetrical 
complications and may impact the neonatal outcome. We were particularly interested in the following outcome 
measures; preterm prelabour rupture of membranes (PPROM) and/or preterm contractions, small-for-gestational-
age (SGA) and neonatal intensive care unit admission (NICU). Moreover, we were interested in changes in 
therapy exposure and obstetrical and neonatal outcome over time. 
PPROM and/or preterm contractions: 
- Antenatal chemotherapy exposure will increase the risk of PPROM and/or preterm contractions. 
- Systemic disease will increase the risk of PPROM and/or preterm contractions. 
- Cervical or abdominal surgery during pregnancy will increase the risk of PPROM and/or preterm 
contractions. 
SGA: 
- Antenatal chemotherapy exposure will increase the risk of SGA. 
- Chemotherapy agents with high placenta crossing will have a stronger effect on SGA (e.g. alkylating 
agents) 
- Starting chemotherapy before the end of placental development may have stronger effect on SGA 
(before 16 weeks GA) 
- Systemic disease will increase the risk of SGA. 
- Diagnosis in the 3rd trimester will decrease the risk of SGA. 
NICU admission: 
- Antenatal chemotherapy exposure will increase the risk of NICU admission. 
- Diagnosis in the 3rd trimester will decrease the risk of NICU admission. 
- Diagnosis in an earlier period of time will increase the risk of NICU admission.  
Changes over time: 
- Type of malignancy will not change over time 
- Stage of disease will decrease over time 
- Chemotherapy exposure will increase over time 
- Premature delivery will decrease over time 
- SGA will increase over time due to increased antenatal chemotherapy exposure. 
4 
 
1.2. Parameters of the percentile calculator. 
 
Table A1. Available data of the included parameters to calculate the birth weight percentiles in 796 cases 
of 955 singleton live births with available GA at birth and birth weight. 
 Study group (n=796) 
 Chemotherapy-exposed (n=353) Non-exposed (n=443) 
Parameters Median (IQR)/ n (%) Available n 
(%) 
Median (IQR)/ n (%) Available n 
(%) 
GA at delivery (days) 256 (242-266)  261 (245-275)  
Birth weight (g) 2632 (2186-3025)  2950 (2430-3340)  
Gender offspring   341 (97%)   416 (94%) 
Male 179 (52%)  204 (49%)   
Female 162 (48%)  212 (51%)   
Ethnicity mother   259 (73%)   283 (64%) 
Caucasian 192 (74%)  208 (73%)   
African 17 (7%)  12 (4%)   
Asian (incl. Russian) 42 (16%)  56 (20%)   
Other 8 (3%)   7 (2%)   
Maternal length (cm) 166 (162-170) 281 (80%) 167 (163-172) 288 (65%) 
Maternal weight at booking (kg) 66 (59-77) 267 (76%) 65 (59-74) 283 (64%) 
Parity   342 (97%)   428 (97%) 
Primiparae 151 (44%)  214 (50%)   
Multiparae 191 (56%)   214 (50%)   
In case of missing values for the different parameters the software uses the average between male and female 
coefficients (gender), other European origin (ethnicity), 165cm (maternal length) and 68kg (maternal weight).  
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1.3. Additional information on multiple imputation of missing values.  
 
For the multiple regression analyses, missing values for covariates and outcomes were addressed using multiple 
imputation based on the method of chained equations.
1
 We used the mice package in R to carry out the 
imputations.
2
 Imputations were based on all the variables included in the procedure, which are the covariates of 
the logistic regression models, as well as other auxiliary variables that are likely predictive of missingness or of 
the value of incomplete variables. The procedure assumes that data are ‘missing at random’ (MAR), which 
means that missing values have occurred randomly conditional on the variables in the imputation procedure.  
We used the following variables in the imputation process: age at diagnosis (years), malignancy type (breast, 
cervix, lymphoma, ovarian, leukaemia, gastro-intestinal, melanoma, thyroid, brain, other haematological 
malignancies, other), systemic disease, abdominal/cervical surgery, period of diagnosis (<2005, 2005-2009, 
2010-2016), diagnosis in the third trimester (yes/no), preterm status (not preterm, spontaneous preterm, 
iatrogenic preterm), birth weight, SGA, NICU admission, PPROM, and six binary variables about the 
administration of different chemotherapeutic agents (anthracyclines, alkylating chemotherapy (non-platinum), 
antimetabolite chemotherapy, platinum, taxanes, and any other chemotherapeutic agents).  
Missing values were imputed 25 times. The regression models are fitted on each of the 25 completed datasets, 
and results were combined using standard Rubin’s rules. Based on recent research, we decided to impute missing 
outcomes and include patients with missing outcome in the analysis.
3
 As a sensitivity analysis, we compared 
results based on imputed data with results based on complete case analysis.
4
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1.4 Obtaining relative risks to express changes over time.  
 
To investigate changes over time, we use univariable log-binomial regression models with year of diagnosis as 
continuous predictor. The coefficient b for year of diagnosis is transformed into a relative risk as a summary of 
the average evolution every five calendar years by calculating exp(b/5). 
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1.5 Participating centres. 
 
Table A2. Overview of participating centres. 
Country City Centre 
Austria Graz University Hospital of Obstetrics and Gynaecology 
Belgium Antwerp Antwerp University Hospital 
Belgium Brussels Cliniques Universitaires St-Luc U.C.L. 
Belgium Leuven University Hospital Leuven 
Chile 
Talcahuano 
Hospital Las Higueras de Talcahuano 
Czech Republic Prague 3rd Medical Faculty Charles University 
Denmark Vejle Vejle Hospital 
France Paris Bichat – Claude-Bernard Hospital 
Germany Freiburg University Hospital of Freiburg 
Great Britain Derby Royal Derby Hospital 
Greece Athens Alexandra General Hospital 
Greece Ioannina Ioannina University Hospital 
Greece Thessaloniki Papageorgiou Hospital 
Italy Milan European Institute of Oncology 
Italy Milan 2 San Raffaele Hospital Milan  
Italy Milan 3 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano 
Italy Monza San Gerardo Hospital 
Italy Turin University of Turin  
Italy Turin 2 Mauriziano 
Poland Gdansk Regional Oncology Center 
Poland Krakow Macierzynstwo Medical Center 
Poland Krakow 2 University Hospital of Krakow  
Poland Warsaw Maria Sklodowska-Curie Memorial Cancer Center  
Russia Moscow Research Center for Obstetrics 
Russia Moscow 2 N.N. Blochin Cancer Research Center 
Spain Madrid La Paz University Hospital 
Spain Madrid 2 MD Anderson Cancer Center  
Switzerland Lausanne University Hospital of Lausanne 
the Netherlands Amsterdam  Antoni van Leeuwenhoek - Netherlands Cancer Institute  
the Netherlands Amsterdam 2 VU University Medical Center 
the Netherlands Amsterdam 3 Academical Medical Center Amsterdam 
the Netherlands Groningen University Medical Center Groningen 
the Netherlands Nijmegen Radboud University Nijmegen Medical Center 
the Netherlands Rotterdam Erasmus Medical Center Rotterdam 
the Netherlands Utrecht University Medical Center Utrecht 
the Netherlands - Other non-academic hospitals in the Netherlands 
United States of America Camden Cooper University Hospital 
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1.6 Recruitment per centre 
 
Figure A1. Plot of inclusion and distribution of registered cases per centre. For Cooper University 
Hospital (Camden, New Jersey, USA), we only received period of diagnosis (<2005, 2005-2009, 2010-2016). 
For this reason we could not show specific dates of diagnosis for this centre. 
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2 Results 
2.1 Missing values.  
 
Table A3. Overview of missing data by period of diagnosis. 
Variable 
Missing values by period of diagnosis, n (%) 
<2005 2005-2009 2010-2016 Overall 
All patients, n 257 376 537 1170 
Age at diagnosis 4 (2) 3 (1) 6 (1) 13 (1) 
Year of diagnosis 15 (6) 8 (2) 11 (2) 34 (3) 
Trimester at diagnosis 21 (8) 27 (7) 24 (4) 72 (6) 
Malignancy type 0 0 0 0 
Systemic disease 8 (3) 14 (4) 23 (4) 45 (4) 
No treatment 0 0 0 0 
Surgery 0 0 0 0 
Abdominal/cervical surgery 0 0 0 0 
Chemotherapy 0 0 0 0 
Radiotherapy 0 0 0 0 
Targeted therapy 0 0 0 0 
Other therapy 0 0 0 0 
Autoimmune disorders 0 0 0 0 
Obstetrical outcome 2 (1) 8 (2) 18 (3) 28 (2) 
Selected malignancies, na 225 329 482 1036 
Disease stage 8 (4) 16 (5) 23 (5) 47 (5) 
All patients with chemotherapy, na 63 132 234 429 
Chemotherapeutic agent(s) 0 2 (2) 4 (2) 6 (1) 
Live births and still births, n 213 320 465 998 
Singleton vs. multiple 0 0 0 0 
Singleton live and still births, n 206 310 453 969 
Each of the obstetrical complicationsb 0 0 0 0 
Singleton live births, n 199 306 450 955 
Preterm delivery <37 weeks 19 (10) 23 (8) 26 (6) 68 (7) 
Spontaneous preterm delivery 19 (10) 26 (8) 26 (6) 71 (7) 
Small-for-gestational-age (SGA) 38 (19) 53 (17) 68 (15) 159 (17) 
NICU admission 52 (26) 80 (26) 103 (23) 235 (25) 
Congenital malformations 70 (35) 78 (25) 86 (19) 234 (25) 
Apgar<7 at 5 minutes 66 (33) 74 (24) 92 (20) 232 (24) 
NICU, neonatal intensive care unit. 
a
 Excluding leukaemia, other haematological, and brain cancer  
b
 Cholestasis, chorio-amnionitis, gestational diabetes, hypertensive disorders, maternal infection, preterm 
prelabour rupture of membranes/preterm contractions, vaginal bleeding, stillbirth, and other complications 
including hypothyroidism, thromboembolic events, skin conditions, poly- and oligohydramnios. There will 
probably have been some missing values, because these complications were only registered when observed, 
whereas absence of a complication was not explicitly registered as such. 
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Table A4. Overview of missing data for neonatal outcomes by centre for singleton live births (n=955). 
 
Center 
N Small-for-
gestational-age 
(SGA) missing, n 
Neonatal intensive 
care unit (NICU) 
admission missing, n 
Missing 
values, % 
University of Turin 37 0 0 0 
AMC Amsterdam 16 0 0 0 
University Medical Center Groningen 3 0 0 0 
Antwerp UH 3 0 0 0 
Alexandra GH (Athens) 2 0 0 0 
Blochin CRC Moscow 2 0 0 0 
Regional Oncology Center (Gdansk) 1 0 0 0 
La Paz UH (Madrid) 10 1 0 5 
Cliniques Universitaires St-Luc U.C.L. (Brussels) 88 5 7 7 
Non academic hospitals (Netherlands) 14 1 1 7 
UH Leuven 164 10 17 8 
University Medical Center Utrecht 16 3 0 9 
San Raffaele Hospital Milan 5 1 0 10 
Erasmus Medical Center (Rotterdam) 42 5 6 13 
Cooper UH 26 0 9 17 
UH Freiburg 10 1 3 20 
San Gerardo Hospital (Monza) 75 18 13 21 
Radboud University Nijmegen 39 7 9 21 
VU Medical Center (Amsterdam) 29 5 7 21 
Vejle Hospital 26 7 4 21 
Charles University (Prague) 76 8 25 22 
Papageorgiou (Thessaloniki) 3 1 1 33 
UH Graz 10 3 4 35 
European Institute of Oncology (Milan) 35 17 9 37 
Research Center for Obstetrics (Moscow) 108 21 62 38 
UH Lausanne 8 2 4 38 
AVL Netherlands Cancer Institute (Amsterdam) 69 32 23 40 
Royal Derby Hospital 5 1 3 40 
Maria Sklodowska-Curie MCC (Warsaw) 10 4 6 50 
MD Anderson (Madrid) 1 0 1 50 
UH Krakow 1 0 1 50 
Macierzynstwo MC (Krakow) 10 1 10 55 
Ioannina UH 8 2 8 63 
Mauriziano (Turin) 2 2 1 75 
Hospital Las Higueras de Talcahuano 1 1 1 100 
Hopital BCB (Paris) 0 - - - 
Ospedale Maggiore (Milan) 0 - - - 
All centers 955 159 235 21 
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2.2 Oncologic data, descriptives. 
 
Table A5. Trimester at diagnosis per malignancy for all patients (n=1170). 
  Trimester at diagnosis, n (%) 
Malignancy Total Before 
pregnancy 
First 
trimester 
Second 
trimester 
Third 
trimester 
Unknown 
Breast cancer 462 23 (5) 112 (26) 180 (42) 117 (27) 30 
Cervical cancer 147 3 (2) 35 (25) 64 (45) 40 (28) 5 
Lymphoma 113 3 (3) 14 (13) 70 (64) 23 (21) 3 
Ovarian cancer 88 0 33 (39) 39 (46) 12 (14) 4 
Leukaemia 68 18 (27) 14 (21) 18 (27) 17 (25) 1 
Gastro-intestinal cancer 49 2 (4) 11 (23) 23 (48) 12 (25) 1 
Melanoma 46 2 (4) 13 (28) 18 (39) 13 (28) 0 
Thyroid cancer 37 3 (8) 14 (38) 18 (49) 2 (5) 0 
Brain cancer 21 1 (5) 2 (10) 9 (43) 9 (43) 0 
Other malignancies 139 21 (19) 18 (16) 51 (46) 21 (19) 28 
All 1170 76 (7) 266 (24) 490 (45) 266 (24) 72 
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Table A6. Treatment combination by malignancy for all patients. (n=1170). 
 Treatment combination, n (%) 
Malignancy n NT S CT S 
CT 
OT TT CT 
TT 
S 
CT 
RT 
S 
RT 
RT CT 
RT 
CT 
RT 
TT 
S 
CT 
TT 
Breast  462 116 
(25) 
89 
(19) 
112 
(24) 
127 
(27) 
- 5 
(1) 
1 
(<1) 
7 
(2) 
2 
(<1) 
2 
(<1) 
- 1 
(<1) 
- 
Cervix  147 83 
(56) 
27 
(18) 
31 
(21) 
4 (3) - - - 1 (1) - - 1 (1) - - 
Lymphoma 113 41 
(36) 
3 (3) 45 
(40) 
2 (2) - - 17 
(15) 
- 2 (2) 1 (1) 1 (1) - 1 (1) 
Ovarian  88 23 
(26) 
44 
(50) 
1 
(11) 
20 
(23) 
`- - - - - - - - - 
Leukaemia 68 22 
(32) 
- 23 
(34) 
- 15 
(22) 
7 
(10) 
- - - 1 (1) - - - 
Gastro-intestinal  49 19 
(39) 
14 
(29) 
9 
(18) 
7 
(14) 
- - - - - - - - - 
Melanoma 46 12 
(26) 
32 
(70) 
- - - - - - 1 (2) 1 (2) - - - 
Thyroid  37 7 
(19) 
29 
(78) 
- - - - - - 1 (3) - - - - 
Brain  21 11 
(52) 
9 
(43) 
- - - - - 1 (5) - - - - - 
Other  139 57 
(41) 
25 
(18) 
11 
(8) 
2 (1) 36 
(26) 
1 (1)  2 (1) 2 (1) 1 (1) 1 (1) - - 
All 1170 391 
(33) 
272 
(23) 
233 
(20) 
162 
(14) 
51 
(4) 
13 
(1) 
18 
(2) 
11 
(1) 
8 
(1) 
6 
(1) 
3 
(<1) 
1 
(<1) 
1 
(<1) 
NT, no treatment; S, surgery; CT, chemotherapy; RT, radiotherapy; TT, targeted therapy; OT, other treatment. 
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2.3 Obstetrical outcome data, descriptives. 
 
Table A7. Termination of pregnancy per malignancy type per period of diagnosis. n(%). 
 1996-2004 2005-2009 2010-2016 
Breast cancer 13/90 (14) 13/150 (9) 10/212 (5) 
Cervical cancer 5/38 (13) 9/43 (21) 9/64 (14) 
Lymphoma 2/24 (8) 2/38 (5) 4/48 (8) 
Ovarian cancer 1/28 (3) - 2/29 (7) 
Leukaemia 3/15 (20) 1/19 (5) 2/32 (6) 
Gastro-intestinal cancer 1/13 (8) 2/9 (22) 2/27 (7) 
Melanoma - 1/13 (7) 1/17 (5) 
Thyroid cancer - 4/15 (27) - 
Brain cancer 1/4 (25) - 1/12 (8) 
All other 6/29 (21) 6/48 (12) 12/57 (20) 
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Table A8. Oncological and obstetrical specification for patients with singleton pregnancy whose pregnancy ended immature, with death of mother or because of 
intra-uterine fetal death. 
Pregnancy ending Malignancy type Treatment during 
pregnancy 
Period of 
diagnosis 
Trimester at 
diagnosis 
Trimester of 
pregnancy 
ending 
Trimester 
at first 
surgery 
Location of surgery Trimester 
at start CT 
Trimester 
at start RT 
Immature Ewing’s sarcoma Chemotherapy 2010 - 2016 First Second   Second  
Immature Acute Myeloid Leukaemia Chemotherapy 2010 - 2016 Second Second   Second  
Immature Breast cancer Surgery 2005 - 2009 First Second Second Breast    
Immature Hodgkin lymphoma No treatment < 2005 First Second     
Immature Hodgkin lymphoma No treatment < 2005 First Second     
Immature Gastric cancer Surgery < 2005 Second Second Second Intra-abdominal   
Immature Oesophageal cancer Surgery 2005 - 2009 Second Second Second Trans-oesophagal   
Maternal death Breast cancer Surgery 2010 - 2016 First Third Third Breast    
Maternal death Melanoma Surgery < 2005 Second Third Third Skin   
Maternal death Brain tumour Surgery 2010 - 2016 Second Third Third Intracerebral   
Maternal death Brain tumour Surgery 2005 - 2009 Second Second Second Intracerebral   
Maternal death Gastric cancer Surgery 2005 - 2009 Second Second Second Intra-abdominal   
IUFD Cervical cancer Chemotherapy and 
radiotherapy 
< 2005 Second Second   Second Second 
IUFD Hodgkin lymphoma Surgery and 
chemotherapy 
< 2005 Second Third Second Lymph node excision Second  
IUFD Essential thrombocythemia Chemotherapy < 2005 Before 
pregnancy 
Third     
IUFD Cervical cancer No treatment 2005 - 2009 Second Third     
IUFD Acute Myeloid Leukaemia No treatment 2005 - 2009 Second Second     
IUFD Primary myelofibrosis Immune therapy < 2005 Unknown Third     
IUFD Kidney cancer Surgery 2010 - 2016 Second Third Second Retroperitoneal   
IUFD, intra-uterine fetal death; CT, chemotherapy; RT, radiotherapy. 
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Table A9. Obstetric complications per malignancy (singleton live & still births, n=969). 
Malignancy n Any 
n (%) 
PPROM/ 
preterm 
contractions 
n (%) 
Maternal 
infection 
n (%) 
Hypertensive 
disorders 
n (%) 
Gestational 
diabetes  
n (%) 
Vaginal 
Bleeding 
n (%) 
Still-
birth 
n (%) 
Chole-
stasis 
n (%) 
Chorio-
amnionitis 
n (%) 
Othera 
n (%) 
Breast cancer 395 81 (21) 46 (12) 10 (3) 7 (2) 7 (2) 3 (1) 1 (<1) 2 (1)  11 (3) 
Cervical 
cancer 
117 27 (23) 8 (7) 3 (3) 3 (3) 3 (3) 7 (6) 2 (2) 1 (1)  8 (7) 
Lymphoma 99 34 (34) 19 (19) 7 (7) 3 (3) 1 (1) 1 (1) 3 (3)   4 (4) 
Ovarian 77 10 (13) 3 (4) 1 (1) 2 (3) 3 (4)   1 (1)  1 (1) 
Leukaemia 53 25 (47) 13 (25) 5 (9) 3 (6) 6 (11) 1 (2) 2 (4) 1 (2)  6 (11) 
Gastro-
intestinal 
40 11 (28) 1 (3) 1 (3) 5 (13) 1 (3)  2 (5)   2 (5) 
Melanoma 40 6 (15) 2 (5) 1 (3)  1 (3) 1 (3)  1 (3)  3 (8) 
Thyroid 33 5 (15) 1 (3) 1 (3) 1 (3) 2 (6)   1 (3)   
Brain 15 4 (27)    2 (13)     3 (20) 
Other 
malignancies 
100 22 (22) 5 (5) 3 (3) 5 (5) 1 (1) 1 (1) 4 (4) 1 (1) 1 (1) 5 (5) 
All 969 225 (23) 98 (10) 32 (3) 29 (3) 27 (3) 14 (1) 14 (1) 8 (1) 1 (<1) 43 (4) 
PPROM, preterm prelabour rupture of membranes.  
a
 Other complications are all reported obstetrical and medical complications, including hypothyroidism, thromboembolic events, skin conditions, poly- and oligohydramnios. 
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2.4 Neonatal outcome data, descriptives. 
 
Table A10. Overview of reported outcomes on the neonatal outcomes (singleton live births, n=955). 
Neonatal complication n (%) 
Preterm delivery 429/887 (48%) 
Spontaneous preterm delivery 53/884 (6%) 
Small-for-gestational-age 167/796 (21%) 
Congenital malformations 32/721 (4%) 
NICU admission 298/720 (41%) 
Apgar score <7 at 5 minutes 18/723 (2%) 
NICU, neonatal intensive care unit. 
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Table A11. Neonatal outcomes stratified by different variables (singleton live births, n=955). 
 Presence of neonatal complication, n/N (%) 
 Premature 
delivery 
SGA NICU Congenital 
Malformations 
Period of diagnosis     
<2005 (n=199) 97/180 (54) 33/161 (20) 73/147 (50) 12/129 (9) 
2005-2009 (n=306) 146/283 (52) 43/253 (17) 93/226 (41) 9/228 (4) 
2010-2016 (n=450) 186/424 (44) 91/382 (24) 132/347 (38) 11/364 (3) 
Age     
<25 (n=57) 29/49 (59) 4/46 (9) 21/39 (54) 2/50 (4) 
25-35 (n=631) 268/587 (46) 106/528 (20) 198/475 (42) 16/467 (3) 
>35 (n=258) 127/244 (52) 55/214 (26) 79/204 (39) 14/202 (7) 
BMI     
<20 (n=80) 40/79 (51) 18/72 (25) 29/64 (45) 2/64 (3) 
20-25 (n=310) 130/285 (46) 46/261 (18) 94/233 (40) 8/255 (3) 
>25 (n=220) 103/209 (49) 49/197 (25) 68/179 (38) 11/181 (6) 
Missing (n=345) 156/314 (50) 54/266 (20) 107/244 (44) 11/221 (5) 
Smoking     
No (n=578) 263/546 (48) 99/505 (20) 181/446 (41) 16/468 (3) 
Yes (n=118) 56/108 (52) 34/95 (36) 42/98 (43) 5/93 (5) 
Missing (n=259) 110/233 (47) 34/196 (17) 75/176 (43) 11/160 (7) 
Substance abuse     
No (n=630) 287/599 (48) 117/550 (21) 197/497 (40) 19/517 (4) 
Yes (n=28) 15/26 (58) 9/24 (38) 15/25 (60) 1/19 (5) 
Missing (n=297) 127/262 (48) 41/222 (18) 86/198 (43) 12/185 (6) 
Tumour type     
Breast cancer (n=394) 184/366 (50) 70/329 (21) 118/317 (37) 17/293 (6) 
Cervical cancer (n=115) 72/109 (66) 21/95 (22) 45/84 (53) 1/80 (1) 
Lymphoma (n=96) 48/93 (52) 25/89 (28) 33/71 (46) 4/84 (5) 
Ovarian cancer (n=77) 21/74 (28) 10/63 (16) 12/56 (21) 3/60 (5) 
Leukaemia (n=51) 25/50 (50) 9/47 (19) 21/45 (47) 3/44 (7) 
Gastro-intestinal cancer (n=38) 29/37 (78) 10/34 (29) 26/36 (72) 1/34 (3) 
Melanoma (n=40) 3/37 (8) 4/27 (15) 4/28 (14) 0/25 (0) 
Thyroid cancer (n=33) 1/33 (3) 3/29 (10) 1/19 (5) 0/19 (0) 
Brain cancer (n=15) 9/15 (60) 1/13 (8) 8/11 (73) 0/12 (0) 
Other malignancies (n=96) 37/73 (51) 14/70 (20) 30/53 (57) 3/70 (4) 
Disease stage     
Systemic (n=175) 331/709 (47) 125/630 (20) 221/576 (38) 26/566 (5) 
Local (n=747) 86/149 (58) 37/142 (26) 72/124 (58) 5/135 (4) 
Missing (n=33) 12/29 (41) 5/24 (21) 5/20 (25) 1/20 (5) 
Treatment during pregnancy     
No (n=264) 137/251 (55) 30/216 (14) 97/192 (51) 9/181 (5) 
Yes (n=691) 292/636 (46) 137/580 (24) 201/528 (38) 23/540 (4) 
Chemotherapy     
No (n=563) 217/507 (43) 68/443 (15) 152/397 (38) 14/393 (4) 
Yes (n=392) 212/380 (56) 99/353 (28) 146/323 (45) 18/328 (5) 
Surgery     
No (n=556) 288/513 (56) 93/463 (20) 197/404 (49) 17/417 (4) 
Yes (n=399) 141/374 (38) 74/333 (22) 101/316 (32) 15/304 (5) 
Abdominal/cervical surgery reported     
No (n=822) 387/767 (50) 146/691 (21) 277/619 (45) 25/610 (4) 
Yes (n=133) 42/120 (35) 21/105 (20) 21/101 (21) 7/111 (6) 
Radiotherapy     
No (n=933) 420/867 (48) 160/778 (21) 291/702 (41) 30/703 (4) 
Yes (n=22) 9/20 (45) 7/18 (39) 7/18 (39) 2/18 (11) 
Targeted therapy     
No (n=922) 417/859 (49) 155/769 (20) 287/696 (41) 31/696 (4) 
Yes (n=33) 12/28 (43) 12/27 (44) 11/24 (46) 1/25 (4) 
Autoimmune disorders reported     
No 415/868 (48) 163/780 (21) 290/704 (41) 31/706 (4) 
Yes 14/19 (74) 4/16 (25) 8/16 (50) 1/15 (7) 
Trimester at diagnosis     
Before pregnancy (n=52) 14/47 (30) 11/45 (24) 13/34 (38) 2/42 (5) 
First (n=175) 68/169 (40) 34/152 (22) 43/135 (32) 5/137 (4) 
Second (n=422) 216/415 (52) 89/369 (24) 144/333 (43) 16/337 (5) 
Third (n=256) 128/253 (51) 33/216 (15) 92/201 (46) 8/178 (4) 
Missing (n=50) 3/3 (100) 0/14 (0) 6/17 (35) 1/27 (4) 
Labour     
Spontaneous (n=280) 52/246 (21) 38/223 (17) 40/190 (21) 10/206 (5) 
Induction (n=288) 132/278 (47) 51/263 (19) 88/242 (36) 8/233 (3) 
Elective CS (n=371) 241/350 (69) 76/307 (25) 169/281 (60) 14/276 (5) 
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Missing (n=16) 4/13 (31) 2/3 (67) 1/7 (14) 0/6 (0) 
Delivery     
Spontaneous head (n=423) 125/404 (31) 68/372 (18) 98/335 (29) 13/331 (4) 
Elective CS (n=411) 267/388 (69) 84/345 (24) 178/310 (57) 16/313 (5) 
Emergency CS (n=48) 17/44 (39) 10/42 (24) 15/35 (43) 1/36 (3) 
Other (n=29) 8/29 (28) 2/28 (7) 4/24 (17) 2/27 (7) 
Missing (n=44) 12/22 (55) 3/9 (33) 3/16 (19) 0/14 (0) 
Offspring gender     
Girl (n=423) 209/404 (52) 82/374 (22) 150/346 (43) 8/335 (2) 
Boy (n=435) 191/406 (47) 77/383 (20) 142/353 (40) 23/366 (6) 
Missing (n=97) 29/77 (38) 8/39 (21) 6/21 (29) 1/20 (5) 
Obstetrical complications reported     
No (n=744) 295/684 (43) 105/602 (17) 207/541 (38) 23/540 (4) 
Yes (n=211) 134/203 (66) 62/194 (32) 91/179 (51) 9/181 (5) 
PPROM reported     
No (n=862) 353/796 (44) 141/711 (20) 254/640 (40) 27/639 (4) 
Yes (n=93) 76/91 (84) 26/85 (31) 44/80 (55) 5/82 (6) 
Gestational age at birth     
<32 weeks (n=59) - 21/52 (40) 48/52 (92) 4/50 (8) 
32-36 weeks (n=370) - 71/334 (21) 201/304 (66) 14/294 (5) 
≥37 weeks (n=458) - 75/398 (19) 42/345 (12) 13/345 (4) 
Missing (n=68) - 0/12 (0) 7/19 (37) 1/32 (3) 
SGA     
No (n=629) 294/617 (48) - 201/522 (39) 21/517 (4) 
Yes (n=167) 92/167 (55) - 79/146 (54) 9/146 (6) 
Missing (n=159) 43/103 (42) - 18/52 (35) 2/58 (3) 
NICU admission     
No (n=422) 107/410 (26) 67/388 (17) - 15/388 (4) 
Yes (n=298) 249/291 (86) 79/280 (28) - 14/257 (5) 
Missing (n=235) 73/186 (39) 21/128 (16) - 3/76 (4) 
SGA, small-for-gestational-age; NICU, neonatal intensive care unit.  
a
 The different congenital malformations are listed in Table A12 of the Appendix 
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Table A12. Reported congenital anomalies: in 721 neonates the presence or absence of malformations was 
reported. 
Treatment during pregnancy Major malformation, n=15, 2 % 
Minor malformation, n=17, 2%                      
Chemotherapy Hip subluxation (n=1) 
Hypospadias (n=1)  
Patent foramen ovale or ASD II (n=1) 
Two little muscular VSD (n=1) 
Accessory ear tag (n=1) 
Pectus Excavatum (n=1) 
Chemotherapy + Surgery (1 unknown) Anorectal atresia (n=1) 
Cleft uvula (n=1) 
Hypospadias (n=1)  
Schizis palatum molle (n=1) 
Unilateral kidney agenesia (n=1) 
Hemihypertrophy of the legs (n=1) 
Limb abnormalities unspecified (n=1) 
Syndactyly (n=1) 
Talipes equinovarus (n=1)  
Ulnar polydactyly (n=1) 
Chemotherapy + Radiotherapy Syndactyly (n=1) 
Chemotherapy + Surgery + Radiotherapy Doubled cartilage ring in both ears (n=1) 
Surgery (1 unknown) Hypospadias, left foot malformation and 
missing left little finger (n=1) 
Multicystic kidney (n=1) 
VSD (n=1) 
Syndactyly (n=1) 
Talipes equinovarus (n=1) 
Radiotherapy - 
Surgery + Radiotherapy - 
Targeted treatment - 
Chemotherapy + Radiotherapy + Targeted treatment VSD, unilateral kidney agenesia (n=1) 
No treatment Hip subluxation (n=1) 
VSD (3mm), ASD (5mm), open duct of 
Botalli (1mm) (n=1) 
Atrial septal aneurysm (n=1) 
Congenital laryngomalacia (n=1) 
Dolichocephaly (n=1) 
Plagiocephaly (n=2) 
Talipes equinovarus (n=1) 
ASD, atrial septal defect; VSD, ventricular septal defect 
Malformations are defects of organs or body parts due to an intrinsically abnormal developmental process. In 
this process, a structure is not formed, is partially formed, or is formed in an abnormal fashion. Major 
malformations are those that have medical and/or social implications. A major malformation is defined as one 
that is incompatible with survival, such as anencephaly; or one requiring major surgery for correction, such as 
cleft palate or congenital heart disease; or one producing major dysfunction (e.g., mental retardation). Minor 
malformations have mostly cosmetic significance. They rarely are medically significant or require surgical 
intervention. They represent part of the normal variation in the general population. (Definition according to 
Eurocat; www.eurocat-network.eu) Major malformations are shown in bold.  
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2.5 Multiple logistic regression analysis. 
 
Table A13. Model coefficients and standard errors for the regression models presented in the main text. 
 PPROM/preterm 
contractions 
Small-for-
gestational-age 
(SGA) 
Neonatal intensive 
care unit (NICU) 
admission 
Covariate Coefficient (SE) Coefficient (SE) Coefficient (SE) 
Malignancy    
Breast cancer Reference Reference Reference 
Cervical cancer -0·30 (0·52) -0·29 (0·37) 0·80 (0·32) 
Lymphoma 0·21 (0·47) 0·15 (0·41) 0·04 (0·34) 
Ovarian cancer -0·51 (0·69) -0·93 (0·52) -0·50 (0·42) 
Leukaemia 0·90 (0·57) -0·39 (0·56) 0·24 (0·44) 
Gastro-intestinal cancer -1·11 (0·91) -0·22 (0·52) 1·96 (0·47) 
Melanoma -0·27 (0·72) -0·11 (0·57) -1·01 (0·54) 
Thyroid cancer -0·65 (0·91) -0·32 (0·65) -1·98 (0·96) 
Other malignancies -0·82 (0·56) -0·20 (0·41) 0·35 (0·34) 
Period of diagnosis    
Before 2005 Reference Reference Reference 
2005-2009 -0·22 (0·31) -0·27 (0·27) -0·32 (0·21) 
2010-2016 -0·26 (0·30) 0·04 (0·26) -0·60 (0·22) 
Age at diagnosis (per 5 years) 0·08 (0·12) 0·31 (0·11) -0·02 (0·09) 
Diagnosis in 3rd trimester -0·45 (0·30) -0·24 (0·25) 0·12 (0·19) 
Systemic disease 0·36 (0·36) 0·62 (0·30) 0·13 (0·27) 
Chemotherapeutic agents    
Alkylating 0·70 (0·46) 0·73 (0·44) -0·13 (0·33) 
Anthracyclines 0·10 (0·49) -0·69 (0·45) 0·19 (0·34) 
Antimetabolite -0·12 (0·34) 0·22 (0·30) 0·03 (0·27) 
Taxanes 0·10 (0·38) 0·73 (0·32) 0·86 (0·30) 
Platinum 0·83 (0·54) 1·14 (0·39) 0·51 (0·39) 
Other 0·39 (0·46) 0·85 (0·41) 0·49 (0·37) 
Abdominal/cervical surgery -0·87 (0·52) 0·27 (0·35) -1·20 (0·30) 
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Figure A2. Estimated small-for-gestational age (SGA) rates by tumour group for an average patient. 
These predictions were based on the multiple logistic regression model for SGA, using average values 
were used for the other covariates. 
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Figure A3. Estimated neonatal intensive care unit (NICU) admission rates by tumour group for an 
average patient. These predictions were based on the multiple logistic regression model for SGA, using 
average values were used for the other covariates. 
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Figure A4. Estimated preterm prelabour rupture of membrane (PPROM) and/or preterm contraction 
rates by tumour group for an average patient. These predictions were based on the multiple logistic 
regression model for SGA, using average values were used for the other covariates. 
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Table A14. Results from the sensitivity analysis presenting multiple regression analysis based on complete 
cases. For preterm prelabour rupture of membranes (PPROM)/preterm contractions, we analysed 
singleton stillbirths and live births, for the neonatal complications we analysed singleton live births. 
 PPROM/preterm 
contractions, 
N=874 (90% of 969) 
Small-for-gestational-age, 
N=751 (79% of 955) 
Neonatal intensive care unit 
admission, 
N=679 (71% of 955) 
Covariate OR 
(95% CI) 
P OR 
(95% CI) 
P OR 
(95% CI) 
P 
Malignancy  
0·11 
 
0·78 
 
<0·0001 
Breast cancer Reference Reference Reference 
Cervical cancer 0·47 (0·15-1·45) 0·84 (0·39-1·79) 2·12 (1·11-4·03) 
Lymphoma 1·20 (0·47-3·08) 1·32 (0·59-2·95) 1·13 (0·53-2·38) 
Ovarian cancer 0·31 (0·06-1·53) 0·44 (0·16-1·24) 0·57 (0·24-1·37) 
Leukaemia 1·96 (0·63-6·07) 0·69 (0·24-1·96) 0·81 (0·32-2·04) 
Gastro-intestinal cancer 0·25 (0·04-1·54) 0·82 (0·30-2·26) 5·98 (2·30-15·5) 
Melanoma 0·41 (0·07-2·30) 1·01 (0·33-3·16) 0·36 (0·12-1·09) 
Thyroid cancer 0·48 (0·08-2·86) 0·71 (0·20-2·54) 0·17 (0·03-1·00) 
Other malignancies 0·30 (0·08-1·08) 0·86 (0·38-1·95) 2·36 (1·18-4·72) 
Period of diagnosis  
0·52 
 
0·22 
 
0·023 
Before 2005 Reference Reference Reference 
2005-2009 0·69 (0·37-1·31) 0·76 (0·44-1·32) 0·67 (0·42-1·08) 
2010-2016 0·73 (0·39-1·35) 1·11 (0·66-1·85) 0·53 (0·33-0·84) 
Age at diagnosis (per 5 years) 1·11 (0·87-1·40) 0·42 1·36 (1·11-1·66) 0·0022 0·96 (0·80-1·15) 0·63 
Diagnosis in 3rd trimester 0·61 (0·33-1·12) 0·11 0·76 (0·47-1·24) 0·27 1·16 (0·77-1·74) 0·49 
Systemic disease 1·49 (0·73-3·04) 0·29 2·04 (1·16-3·60) 0·014 1·76 (1·01-3·07) 0·040 
Chemotherapeutic agents  
0·036a 
 
0·00023a 
 
0·022a 
Alkylating 1·78 (0·69-4·59) 2·04 (0·87-4·83) 0·78 (0·38-1·63) 
Anthracyclines 1·09 (0·40-3·01) 0·54 (0·22-1·35) 1·24 (0·58-2·64) 
Antimetabolite 0·93 (0·48-1·80) 1·25 (0·70-2·24) 1·07 (0·62-1·85) 
Taxanes 1·18 (0·55-2·53) 2·05 (1·09-3·86) 2·75 (1·47-5·16) 
Platinum 3·47 (1·09-11·0) 2·78 (1·26-6·17) 1·33 (0·59-3·00) 
Other 1·68 (0·67-4·19) 2·02 (0·88-4·66) 1·42 (0·63-3·20) 
Abdominal/cervical surgery 0·56 (0·20-1·57) 0·27 1·30 (0·68-2·48) 0·42 0·30 (0·15-0·57) 0·00011 
a
 Joint test of the six chemotherapeutic agent variables. 
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2.6 Changes in 20 years of treatment in pregnant cancer patients. 
 
Table A15. Differences in treatment and obstetrical outcome between patients diagnosed before 2005, 
between 2005-2009 and 2010-2016. 
 Period of diagnosis, n/N (%)  
Variable <2005 2005-2009 2010-2016 Total Average change 
every 5 calendar 
years (95% CI) 
 All patients (n=1170) 
Age at diagnosis (years) 32 (28-36) 33 (29-36) 33 (29-36) 32 (29-36) +0·3 (0·0-0·7) 
Malignancy       
Breast cancer 91/257 (35) 151/376 (40) 220/537 (41) 462/1170 (39) RR 1·04 (0·96-1·12) 
Cervical cancer 38/257 (15) 44/376 (12) 65/537 (12) 147/1170 (13) RR 0·94 (0·80-1·10) 
Lymphoma 24/257 (9) 38/376 (10) 51/537 (9) 113/1170 (10) RR 0·95 (0·79-1·13) 
Ovarian cancer 29/257 (11) 29/376 (8) 30/537 (6) 88/1170 (8) RR 0·79 (0·63-0·98) 
Leukaemia 15/257 (6) 20/376 (5) 33/537 (6) 68/1170 (6) RR 0·99 (0·78-1·27) 
Gastro-intestinal cancer 13/257 (5) 9/376 (2) 27/537 (5) 49/1170 (4) RR 1·31 (0·91-1·90) 
Melanoma 13/257 (5) 14/376 (4) 19/537 (4) 46/1170 (4) RR 0·89 (0·66-1·19) 
Thyroid cancer 1/257 (<1) 15/376 (4) 21/537 (4) 37/1170 (3) RR 1·65 (1·11-2·43) 
Brain cancer 4/257 (2) 5/376 (1) 12/537 (2) 21/1170 (2) RR 0·97 (0·62-1·51) 
All other 29/257 (11) 51/376 (14) 59/537 (11) 139/1170 (12) RR 1·00 (0·85-1·17) 
Systemic disease 58/249 (23) 73/362 (20) 101/514 (20) 232/1125 (21) RR 0·91 (0·80-1·02) 
Treatment during pregnancy      
No treatment 111/257 (43) 122/376 (32) 158/537 (29) 391/1170 (33) RR 0·84 (0·78-0·91) 
Any treatment 146/257 (57) 254/376 (68) 379/537 (71) 779/1170 (67) RR 1·10 (1·05-1·15) 
Surgery 99/257 (39) 154/376 (41) 201/537 (37) 454/1170 (39) RR 0·99 (0·92-1·07) 
Chemotherapy 63/257 (25) 132/376 (35) 234/537 (44) 429/1170 (37) RR 1·31 (1·20-1·43) 
Radiotherapy 10/257 (4) 10/376 (3) 9/537 (2) 29/1170 (2) RR 0·67 (0·47-0·96) 
Targeted or anti-hormonal 
therapy 
1/257 (<1) 10/376 (3) 22/537 (4) 33/1170 (3) RR 2·10 (1·34-3·30) 
Other therapya 11/257 (4) 21/376 (6) 20/537 (4) 52/1170 (4) RR 0·85 (0·65-1·11) 
 All patients with chemotherapy (n=429) 
GA at last chemotherapy cycle 
(days) 
215 (193-233) 225 (210-240) 230 (208-242) 226 (207-239) +2·6 (-1·1-6·3) 
 All patients with solid malignancies except brain cancers (n=1036) 
Disease stage      
I 90/217 (41) 119/313 (38) 160/459 (35) 369/989 (37) RR 0·96 (0·88-1·04) 
II 61/217 (28) 114/313 (36) 161/459 (35)  336/989 (34) RR 1·06 (0·97-1·17) 
III 36/217 (17) 49/313 (16) 80/459 (17) 165/989 (17) RR 1·00 (0·86-1·16) 
IV 30/217 (14) 31/313 (10) 58/459 (13) 119/989 (12) RR 0·95 (0·80-1·14) 
 All singleton pregnancies (n=1107) 
Live birth 199/242 (82) 306/347 (88) 450/500 (90) 955/1089 (88) RR 1·04 (1·01-1·06) 
Miscarriage 8/242 (3) 5/347 (1) 6/500 (1) 19/1089 (2) RR 0·62 (0·39-0·99) 
Termination of pregnancy 27/242 (11) 30/347 (9) 38/500 (8) 95/1089 (9) RR 0·85 (0·70-1·03) 
Stillbirth (excl. died w/ mother) 7/242 (3) 4/347 (1) 3/500 (1) 14/1089 (1) RR 0·48 (0·29-0·79) 
 All singleton live and stillbirths (n=969) 
PPROM 20/206 (10) 31/310 (10) 47/453 (10) 98/969 (10) RR 0·97 (0·80-1·18) 
Any obstetrical complication 44/206 (21) 64/310 (21) 117/453 (26) 225/969 (23) RR 1·05 (0·93-1·19) 
 All singleton live births (n=955) 
Preterm live birth 97/180 (54) 143/280 (51) 186/424 (44) 426/884 (48) RR 0·93 (0·86-0·99) 
Iatrogenic preterm live births 88/180 (49) 128/280 (46) 157/424 (38) 373/884 (42) RR 0·91 (0·84-0·98) 
SGA 33/161 (20) 43/253 (17) 91/382 (24) 167/796 (21) RR 1·16 (0·99-1·35) 
NICU 73/147 (50) 93/226 (41) 132/347 (38)  298/720 (41) RR 0·91 (0·83-0·99) 
Congenital malformations 12/129 (9) 9/228 (4) 11/364 (3) 32/721 (4) RR 0·62 (0·44-0·88) 
Low Apgar 2/133 (2) 5/232 (2) 11/358 (3) 18/723 (2) RR 1·00 (0·62-1·62) 
RR, relative risk; CI, confidence interval. 
Statistics shown are median (interquartile range) for continuous variables, and n/N (%) for categorical variables. Missing values are 
excluded, hence the denominator is always shown.  
a Only interferon.  
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2.7 Cohorts of cancer during pregnancy in the literature. 
 
Table A16. General overview of articles on cohorts of cancer during pregnancy containing over 50 patients. 
Year Authors No. of 
patients 
Years of 
inclusion 
Type of study Countries Malignancy Management 
given during 
pregnancy 
Pregnancy outcome Neonatal outcome w/o 
SGA 
SGA 
2017 de Haan et al.a 5 60 1994-2015 Retrospective 
cohort 
Belgium, 
Czech 
Republic, 
Denmark, 
Italy, the 
Netherlands, 
Poland 
Melanoma NT: 7 (11%) 
S: 49 (82%)  
RT: 1 (2%) 
S + CT: 1 (2%) 
S + RT: 2 (3%) 
TOP: 3 (5%) 
SB: 1 (2%) 
 
LB: 49 (84%) 
- 9 (18%) Preterm 
- 17 (40%) CS 
No congenital anomalies or 
neonatal deaths 
Non-CT exposed: 2 (4%) 
 
2016 Lu et al.6  984 1973-2012 Population 
based 
retrospective 
cohort 
Sweden Multiple Not mentioned Increased SGA related 
stillbirth (IRR 4·9, 95% 
CI 2·2 – 11·0) 
 
  
Increased preterm birth 
(IRR 5·8, 95% CI 5·3 – 
6·5) 
- Mainly iatrogenic 
 
Increased CS rate (40% 
vs. 12%) 
Increased neonatal mortality 
(IRR 2·7, 95% CI 1·3 – 5·6) 
- 89% prematurity 
related 
Increased preterm SGA 
(RR 3·0, 95% CI 2·1 – 
4·4) 
- Mainly 
haematological and 
ovarian cancers 
 
No increased term SGA 
(RR 1·0, 95% CI 0·7 – 
1·3)  
2016 Garofalo et al.7 60 2001-2016 Single centre 
retrospective 
cohort 
Italy Multiple NT: 24 (40%) 
S: 14 (23%) 
CT: 12 (20%) 
S + CT: 10 
(17%) 
Miscarriage: 1 (2%) 
SB: 1 (2%) 
 
LB: 58  
- 49 (83%) preterm 
birth 
- 52 (85%) CS 
Congenital malformations: 
3 (5%)  
NICU: 22 (35%) 
32% (in both CT and non-
CT exposed group) 
 
 
2016 Shim et al. 87 1995-2013 Retrospective 
cohort 
South Korea Multiple NT: 63 (73%) 
S: 10 (11%) 
CT: 8 (9%) 
S + CT: 6 (7%) 
Miscarriage: 1 (1%) 
TOP: 18 (21%)  
 
LB: 68 78%): 
- 34 (50%) overall 
preterm 
- 25 (29%) 
iatrogenic preterm 
- 40 (59%) CS 
Of the preterm babies: 
- NICU: 24 (71%)  
- 3 (9%) neonatal 
deaths 
Not mentioned 
2015 Amant et al.a 8 129 2005-2015 Prospective 
matched cohort 
Belgium, 
Czech 
Republic, 
Italy, the 
Multiple NT: 14 (11%) 
S: 13 (10%)  
CT: 41 (32%) 
RT: 1 (1%) 
79 (61%) preterm 
deliveries 
No increase in congenital 
malformations 
No overall increase (22% 
vs. 15%, p=0·16) 
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Netherlands OT: 2 (2%) 
S + CT: 48 
(37%) 
S + RT: 3 (2%) 
CT + RT: 3 (2%) 
S + CT + RT: 4 
(3%) 
2015 Nazer et al.9 179 2003-2011 Population 
based 
retrospective 
cohort 
Canada Ovarian Not mentioned Increased risk of CS (OR 
5·92, 95% CI 4·17-8·41) 
 
Increased risk of 
prematurity (OR 2·24, 
95% CI 1·48 – 3·42)  
 
No increased risk of 
PPROM or stillbirth 
Not mentioned No increased risk 
2015 El-Messidi et 
al.10  
427 2003-2011 Population 
based 
retrospective 
cohort 
Canada Non-Hodgkin 
lymphoma 
Not mentioned Increase risk of CS (OR 
1·37, 95% CI 1·13 – 
1·67) 
 
Increased risk of 
prematurity (OR 2·50, 
95% CI 1·94 – 3·22) 
 
No increased risk of IOL 
 
Increased risk of stillbirth 
(OR 2·71, 95% CI 1·12 – 
6·55)  
No increased risk of 
congenital malformations 
No increased risk 
2015 Bannister-
Tyrrell et al.11  
195 1994-2008 Population 
based 
retrospective 
cohort 
Australia Melanoma Not mentioned No increased risk of still 
birth, planned birth, CS, 
prematurity 
Not mentioned  No increased risk 
 
75% higher odds on LGA 
2015 El-Messidi et 
al.12 
638 2003-2011 Population 
based 
retrospective 
cohort 
Canada Hodgkin 
lymphoma 
Not mentioned Increased risk of 
prematurity (OR 1·93, 
95% CI 1·53 – 2·42) 
 
No increased risk of CS 
or IOL 
No increased risk of 
congenital malformations or 
neonatal death 
No increased risk 
2014 Murthy et al.a 13 81 1992-2010 Single centre 
prospective 
cohort  
USA Breast CT: 81 (100%) 28 (35%) premature 
deliveries 
 
33% CS delivery 
No increased risk of 
congenital malformations 
(n=3) 
 
NICU: 9 (14%) 
Not mentioned 
2013 Evens et al.14  90 1999-2011 Retrospective 
cohort 
USA Lymphoma NT: 34 (38%) 
CT: 31 (34%) 
RT: 5 (6%) 
OT: 1 (1%) 
TOP: 6 (7%) 
LB: 84 (93%): 
- 30% Iatrogenic 
prematurity 
NICU: 11%, no difference 
between antenatal and 
deferred therapy 
 
No difference in birth 
weight between antenatal 
and deferred therapy 
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CT + RT: 3 (3%) 
CT + OT: 14 
(16%) 
CT + RT + OT: 1 
(1%) 
UNK: 1 (1%) 
- 14% Spontaneous 
prematurity 
 
No difference in PPROM 
or other obstetrical 
complications 
 
33% CS rate  
Congenital malformations: 
2 (2%) (both in patients 
with antenatal CT, in 
second trimester) 
Trent to difference in SGA 
but NS (41% vs. 9%, 
p=0·09) 
2012 Lee et al.15 499 1994-2008 Population 
based 
retrospective 
cohort 
Australia Multiple Not mentioned Increased risk of IOL 
(aOR 1·27, 95% CI 1·03 
– 1·56) 
 
Increased risk of CS (aOR 
2·08, 95% CI 1·70 – 
2·54) 
 
Increased risk of 
iatrogenic prematurity 
(aOR 11·53, 95% CI 8·81 
– 15·11) 
But no increased risk of 
spontaneous prematurity 
No increased risk of 
perinatal death 
No increased risk 
 
Increased risk LGA (aOR 
1·47, 95% CI 1·14 81 – 
1·89) 
 
2012 Loibl et al.a 16 447 2003-2011 Retrospective 
cohort 
Multiple Breast Of 413 early 
stage: 
NT: 99 (24%) 
S: 100 (24%) 
CT: 118 (29%) 
S + CT: 79 
(19%) 
UNK: 17 (4%) 
Miscarriage/TOP: 51 
(11%) 
SB: 3 (1%) 
UNK: 11 (2%) 
 
LB: 382 (86%) 
- 51% preterm 
delivery 
- 46% CS 
 
Symptoms of preterm 
delivery higher in CT 
group (p=0·012) 
Neonatal deaths: 2 (1%) 
(non-treatment related) 
 
Side effects, malformations 
or new-born complications: 
40 (10%) 
- More common in 
preterm delivered 
babies (16% vs. 5%, 
p=0·0002) 
- More common in CT 
exposed babies (15% 
vs. 4%, p=0·00045) 
No difference in overall 
SGA (9% vs. 4%, p=0·10) 
 
Increase in CT related 
SGA (p=0·018) 
 
 
2012 Abdel-Hady el 
et al.17 
118 2003-2011 Prospective 
cohort 
Egypt Multiple NT: 44 (37%)  
S: 13 (11%) 
CT: 61 (52%) 
TOP: 26 (22%) 
 
LB: 92 (78%) 
- 18 iatrogenic 
prematurity 
No difference between CT 
exposed and healthy 
premature control group in: 
- Birth weight 
- Neonatal survival 
- NICU admission 
- Congenital 
anomalies 
No difference between CT 
exposed and healthy 
premature control group 
2012 Amant et al.a 18 68 1994-2011 Prospective 
cohort 
Belgium, 
Czech 
Republic, the 
Netherlands  
Multiple CT: 34 (50%) 
S + CT: 27 
(40%) 
CT + RT: 1 (1%) 
S +CT + RT: 6 
45 (66%) premature 
deliveries 
Congenital malformations: 
7 (10%), similar to general 
population 
Increased rate compared to 
general population (21%, 
p=0·009) 
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(9%) 
2012 Avilés et al.19 58 1975-2008 Retrospective 
cohort 
Mexico Haematological CT: 58 (100%)  
(first trimester) 
SB: 4 (7%) 
LB: 54 (93%) 
- 4 (7%) extreme 
prematurity 
No congenital anomalies or 
neonatal deaths 
 
NICU: 4 (7%) (in extreme 
premature born children) 
10 (19%) 
2012 Cardonick et 
al.a 20 
109 1997-2010 Single centre 
retrospective 
cohort 
USA Breast CT: 109 (100%) 20 (18%) overall 
spontaneous preterm 
delivery 
Congenital malformations: 
4 (4%), no difference 
between groups 
Neonatal deaths: 1 (1%)  
7 (6%) 
2010 Cardonick et 
al.a 21 
130 
(including 6 
weeks 
postpartum) 
1996-2003 Prospective + 
retrospective 
cohort 
USA Breast Of the LB 
(n=116): 
NT: 3 (3%)  
S: 9 (8%) 
CT: 27 (23%) 
S + CT: 77(66%) 
Miscarriage: 6 (4%) 
TOP: 10 (8%) 
UNK: 1 (1%) 
 
LB: 113 (87%): 
- Mean GA at 
delivery: 35·8 +/- 
1·9 weeks 
- 1 spontaneous 
preterm delivery 
- 37 (33%) CS 
No increased rate of 
congenital malformation 
(4%) compared to general 
population 
8 (10%), all CT exposed 
No increase compared to 
general population  
2010 Van Calsteren 
et al.a 22 
215 1998-2008 Retrospective 
cohort 
Multiple Multiple All LB (n=180): 
NT: 58 (31%) 
S: 49 (27%)  
CT: 33 (18%) 
RT: 3 (2%) 
OT: 5 (3%) 
S + CT: 25 
(14%) 
S + RT: 3 (2%) 
CT + RT: 1 (1%) 
S + CT + RT: 3 
(2%) 
Miscarriage: 5 (2%) 
TOP: 30 (14%) 
 
LB: 180 (84%) 
- 54% prematurity 
- 72% Induction of 
labour/CS 
 
In CT exposed 
pregnancies preterm 
labour was increased 
(12%, p=0·012) 
Of all LB: 
- NICU: 92 (51%) 
- NICU reason 
mainly 
prematurity 
(85%) 
 
No increased rate of 
congenital malformations  
Increase in CT exposed 
children (24%, p=0·001) 
2010 Cardonick et 
al.23 
231  1995-2008 Nationwide 
retrospective 
cohort 
USA Multiple CT: 152 (66%) 
UNK: 79 (34%) 
TOP: 12 (5%) 
 
In CT exposed 
pregnancies (n=157): 
- SB: 1 (1%) 
- 9 (6%) 
Spontaneous 
prematurity  
 
No difference in mean 
GA at delivery between 
CT and non-CT exposed 
pregnancies: 
35·8 +/- 2·8 weeks vs. 
36·5 +/- 3·3 weeks 
No increased rate in CT 
group of: 
- Congenital 
malformations: 6 
(4%) 
- Neonatal deaths: 
1 (1%) 
 
No increased rate in CT vs. 
non-CT (8% vs. 7%)  
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2006 Hahn et al.a 24 57 1992- Single centre 
cohort 
USA Breast CT: 19 (33%) 
S + CT: 38 
(67%) 
No miscarriage or SB 
 
Increase of 12% CS rates 
(40% vs. 28%)  
 
Prematurity not 
mentioned  
No perinatal deaths 
 
Congenital malformations: 
1 (2%) (Down syndrome)  
 
Not mentioned 
2005 Dalrymple et 
al.25 
136 1991-1999 Population 
based 
retrospective 
cohort 
USA Cervix Not mentioned Increased risk of CS (OR 
3·7, 95% CI 2·6 – 5·2) 
 
Increased risk of 
prematurity (OR 4·7, 95% 
CI 3·2 – 6·7), both 
spontaneous and 
iatrogenic 
 
Increased risk of still birth 
(OR 5·5, 95% CI 2·0 – 
14·8) 
Increased risk of neonatal 
admission (OR 5·2, 95% CI 
3·6 – 7·5) 
 
 
Increased risk of SGA (OR 
5·5, 95% CI 3·7 – 8·1) 
 
Increased risk for extreme 
SGA (OR 6·9, 95% CI 3·7 
– 12·8) 
2005 Yasmeen et 
al.26 
129 1991-1999 Retrospective 
population 
matched cohort  
USA Thyroid NT: 33 (26%) 
S: 96 (74%) 
No increased risk of 
prematurity or CS 
No increased risk of 
neonatal death 
No increased risk 
2005 O'Meara et 
al.27 
145 1991-1999 Population 
based 
retrospective 
cohort 
USA Melanoma S: 141 (97%) 
UNK: 4 (3%) 
No increased risk 
compared to healthy 
controls on: 
- SB 
- Prematurity 
- CS  
No increased risk compared 
to healthy controls on: 
- NICU admission 
- Neonatal death 
No increased risk 
compared to healthy 
controls 
2000 Ibrahim et al.28 
 
72 1992-1996 Retrospective 
matched cohort 
Saudi Arabia Breast NT: 55 (76%)  
S: 10 (14%) 
S + CT: 7 (10%) 
TOP: 34 (47%)  
LB: 38 (53%), all 
spontaneous vaginally 
delivered  
No congenital 
malformations 
Not mentioned 
NT, no treatment during pregnancy; S, surgery during pregnancy; CT, chemotherapy during pregnancy; RT, radiotherapy during pregnancy; OT, other treatment during 
pregnancy; SB, still birth; LB, live birth; CS, caesarean section; SGA, small-for-gestational-age, NICU, neonatal intensive care unit. 
a 
Data from the same research groups or medical centres may be used in different studies.  
Reported numbers and interpretation of numbers are as reported in the studies.  
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3 Participating investigators 
 
Table A17. List of investigators per institution. 
INCIP member Hospital City Country 
Achtari, C. University Hospital of Lausanne Lausanne Switzerland 
Alonso Salvador, S. MD Anderson Cancer Center  Madrid Spain 
Altintas, S. Antwerp University Hospital Antwerp Belgium 
Amant, F. University Hospital Leuven Leuven Belgium 
Baljewicz-Nowak, M. University Hospital of Krakow, Macierzynstwo Medical 
Center 
Krakow Poland 
Benedicic, C. University Hospital of Obstetrics and Gynaecology Graz Austria 
Bjelic-Radisic, V. University Hospital of Obstetrics and Gynaecology Graz Austria 
Boere, I. Erasmus Medical Center Rotterdam Rotterdam the Netherlands 
Cardonick, E.  Cooper University Hospital Camden United States of America 
Ceppi, L. San Gerardo Hospital Monza Italy 
Dahl Steffensen, K.  Vejle Hospital Vejle Denmark 
Fountzilas, G. Papageorgiou Hospital Pavlos Melas Greece 
Fruscio, R.  San Gerardo Hospital Monza Italy 
Fumagalli, M. Fondazione IRCCS Ca' Granda Ospedale Maggiore 
Policlinico Milano 
Milan Italy 
Groot, C. de VU University Medical Center Amsterdam the Netherlands 
Haidopoulos, D. Alexandra General Hospital Athens Greece 
Halaska, M. 3rd Medical Faculty Charles University Prague Czech Republic 
Hasenburg, A. University Hospital of Freiburg Freiburg Germany 
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